CHUGAI PHARMACEUTICAL CO., LTD. Corporate Communications Dept.

1-1, Nihonbashi-Muromachi 2-chome, Chuo-ku Tokyo, 103-8324 Japan

Roche Group

TEL:+81-(0)3-3273-0881 FAX:+81-(0)3-3281-6607 E-mail:pr@chugai-pharm.co.jp URL:http://www.chugai-pharm.co.jp

Translation

Supply Plan of "Tamiflu®" Anti-influenza Drug for the 2012-2013 Season

November 1, 2012 (Tokyo) - Chugai Pharmaceutical Co., Ltd. ("Chugai") [Head office: Chuo-ku, Tokyo; Chairman & CEO: Osamu Nagayama] announced today that a supply plan of the anti-influenza drug "Tamiflu® Capsule 75" and "Tamiflu® Dry Syrup 3%" (generic name: oseltamivir phosphate) imported from F. Hoffmann-La Roche Ltd. [Head Office: Basel, Switzerland. CEO: Severin Schwan] for the 2012-2013 season (hereafter, this season) for Japan has been prepared.

Supply plan for this season (as of end of October, 2012)

Tamiflu[®] Capsule 75 8.0 million treatment courses Tamiflu[®] Dry Syrup 3% 3.0 million treatment courses

Total of 11.0 million treatment courses

Chugai will consider supplying further if the size of the epidemic of influenza expands.

Chugai is determined to be ready for the supply of Tamiflu® in preparation for the epidemic of influenza.

Tamiflu[®] is trademark of F. Hoffmann-La Roche Ltd., Basel, Switzerland.